These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 23155225)
1. Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC. Evans T Anticancer Res; 2012 Nov; 32(11):4629-38. PubMed ID: 23155225 [TBL] [Abstract][Full Text] [Related]
2. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer. Gadgeel SM Clin Lung Cancer; 2012 Mar; 13(2):96-106. PubMed ID: 22056889 [TBL] [Abstract][Full Text] [Related]
3. The potential of antiangiogenic therapy in non-small cell lung cancer. Giaccone G Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076 [TBL] [Abstract][Full Text] [Related]
4. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Gridelli C; Maione P; Rossi A; De Marinis F Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612 [TBL] [Abstract][Full Text] [Related]
5. New antiangiogenetic agents and non-small cell lung cancer. Gridelli C; Rossi A; Maione P Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002 [TBL] [Abstract][Full Text] [Related]
6. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Langer C; Soria JC Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973 [TBL] [Abstract][Full Text] [Related]